113 related articles for article (PubMed ID: 27997009)
61. Lung Cancer: Understanding Its Molecular Pathology and the 2015 WHO Classification.
Inamura K
Front Oncol; 2017; 7():193. PubMed ID: 28894699
[TBL] [Abstract][Full Text] [Related]
62. Lung Adenocarcinoma Tumor Origin: A Guide for Personalized Medicine.
Seguin L; Durandy M; Feral CC
Cancers (Basel); 2022 Mar; 14(7):. PubMed ID: 35406531
[TBL] [Abstract][Full Text] [Related]
63. On the Origin of Lung Cancers.
Pennycuick A; Janes SM
Am J Respir Crit Care Med; 2020 Mar; 201(6):646-647. PubMed ID: 31801024
[No Abstract] [Full Text] [Related]
64. Prioritizing mutational profiling for targeted therapy of lung adenocarcinoma.
Sinjab A; Tfayli A
J Thorac Dis; 2019 Mar; 11(Suppl 3):S216-S219. PubMed ID: 30997180
[No Abstract] [Full Text] [Related]
65. Non-small cell lung cancer genomics around the globe: focus on ethnicity.
Araujo LH; Carbone DP
J Thorac Dis; 2017 Apr; 9(4):E392-E394. PubMed ID: 28523187
[No Abstract] [Full Text] [Related]
66. Genomics of lung cancer.
Fong KM; Bowman RV; Yang IA
J Thorac Dis; 2017 Feb; 9(2):E155-E157. PubMed ID: 28275503
[No Abstract] [Full Text] [Related]
67. ALK inhibitors in the treatment of advanced NSCLC.
Gridelli C; Peters S; Sgambato A; Casaluce F; Adjei AA; Ciardiello F
Cancer Treat Rev; 2014 Mar; 40(2):300-6. PubMed ID: 23931927
[TBL] [Abstract][Full Text] [Related]
68. Genomic profiling of lung adenocarcinoma patients reveals therapeutic targets and confers clinical benefit when standard molecular testing is negative.
Lim SM; Kim EY; Kim HR; Ali SM; Greenbowe JR; Shim HS; Chang H; Lim S; Paik S; Cho BC
Oncotarget; 2016 Apr; 7(17):24172-8. PubMed ID: 26992220
[TBL] [Abstract][Full Text] [Related]
69. [Correlation of clinicopathologic features and driver gene mutation in non-small cell lung cancer].
Chen LF; Chen XY; Yu XB
Zhonghua Bing Li Xue Za Zhi; 2016 Apr; 45(4):221-5. PubMed ID: 27033383
[TBL] [Abstract][Full Text] [Related]
70. Targeted therapy for NSCLC with driver mutations.
Minuti G; D'Incecco A; Cappuzzo F
Expert Opin Biol Ther; 2013 Oct; 13(10):1401-12. PubMed ID: 23930754
[TBL] [Abstract][Full Text] [Related]
71. [Genomics of lung adenocarcinoma: pathogenetic significance and clinical applications.].
Palmirotta R; Acquafredda S; Argentiero A; Carella C; Lanotte L; Pappagallo N; Quaresmini D; Silvestris F
Recenti Prog Med; 2016 Dec; 107(12):652-672. PubMed ID: 27997009
[TBL] [Abstract][Full Text] [Related]
72. Management and future directions in non-small cell lung cancer with known activating mutations.
Gerber DE; Gandhi L; Costa DB
Am Soc Clin Oncol Educ Book; 2014; ():e353-65. PubMed ID: 24857124
[TBL] [Abstract][Full Text] [Related]
73.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
74.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
75.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
76.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
77.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
78.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
79.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
80.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
